ADDF-Harrington Scholar Program Open to Applications

 

Founded in 1998 and based in the US, the Alzheimer's Drug Discovery Foundation (ADDF) seeks to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease.

The ADDF-Harrington Scholar Award Program seeks to advance academic discoveries into medicines for Alzheimer's disease and related dementias. Academic investigators based in the United States, Canada and the United Kingdom can receive funding and committed project support from a team of pharmaceutical industry experts through a collaboration between ADDF and the Harrington Discovery Institute.

Proposals should show potential to advance discovery into meaningful therapeutics to treat, prevent or slow Alzheimer's disease or related dementias. Teams should possess intellectual property (IP) or have potential for novel IP that has not yet been licensed to a for-profit entity.

The 2021 round places high priority on targets related to emerging therapeutic areas for dementia, particularly:

  • Epigenetics (including nucleosome dynamics, chromatin remodelling, DNA methylation, histone modifications (methylation, acetylation, phosphorylation, ubiquitylation, sumoylation), bromodomain protein modulators and isocitrate dehydrogenase modulators).
  • Proteostasis (including autophagy, lysosomal biogenesis, proteasomal degradation, post-translational modification associated with proteostasis, protein folding/misfolding, ER stress and extracellular clearance).

Other novel targets are encouraged. These include, but are not limited to:

  • Neurovascular health
  • Neuroprotection
  • Synaptic activity and neurotransmitters
  • Inflammation
  • Mitochondria and metabolic function
  • ApoE
  • Other ageing targets (eg senescent cells)

The scheme is open to academic investigators at accredited medical centres, research institutions and universities in the United States, Canada and the United Kingdom. The lead investigator must have an MD, PhD or equivalent.

Researchers working on drug development programmes that are relevant to but not presently focused on the Alzheimer's field are encouraged to apply.

Up to $600,000 is available over two years. In addition, award recipients receive dedicated support from a team of industry experts, which is tailored to the specific needs of the project.

Application is via a two-stage process: a Letter of Intent followed by an invited full proposal. The Letter of Intent deadline is 23 April 2021 (17:00 EDT) and the invited full proposal deadline is 30 July 2021 (17:00 EDT).

 

More information about this research funding opportunity and the application process is available on the RESEARCHconnect funding information platform. RESEARCHconnect provides up-to-the minute content, insight and analysis on research funding news and policy. To find out more about how RESEARCHconnect can keep you in the know, and subscription fees, contact us today.